Dual roles for immunity in gastrointestinal cancers

Journal of Clinical Oncology

Volumn 28, Issue 26, 2010, Pages 4045-4051

  Ferrone, Cristina ^a   Dranoff, Glenn ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17F; INTERLEUKIN 23; PROTEIN P55; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLORECTAL CARCINOMA; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM CANCER; ENTERITIS; GRANULOCYTE; HUMAN; IMMUNITY; INFLAMMATION; INNATE IMMUNITY; LIVER CELL CARCINOMA; MACROPHAGE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; TH17 CELL; TUMOR IMMUNITY; COLORECTAL TUMOR; GASTROINTESTINAL TUMOR; IMMUNOLOGY; LIVER TUMOR; STOMACH TUMOR; T LYMPHOCYTE; TUMOR ESCAPE;

CARCINOMA, HEPATOCELLULAR; COLORECTAL NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNITY; INFLAMMATION; LIVER NEOPLASMS; STOMACH NEOPLASMS; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 77956905415     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.27.9992     Document Type: Review

References (89)

1. Balkwill F, Mantovani A: Inflammation and cancer: Back to Virchow? Lancet 357:539-545, 2001
2. Dvorak HF: Tumors: Wounds that do not heal: Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650-1659, 1986
3. Ekbom A: Risk of cancer in ulcerative colitis. J Gastrointest Surg 2:312-313, 1998
4. El-Omar EM, Carrington M, Chow WH, et al: The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature 412:99, 2001
5. Bosch FX, Ribes J, Diaz M, et al: Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127:S5-S16, 2004 (Pubitemid 39423365)
6. Lowenfels AB, Maisonneuve P, Cavallini G, et al: Pancreatitis and the risk of pancreatic cancer: International Pancreatitis Study Group. N Engl J Med 328:1433-1437, 1993 (Pubitemid 23143844)
7. Lagergren J, Bergstrom R, Lindgren A, et al: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340:825-831, 1999 (Pubitemid 29142625)
8. Frisch M, Glimelius B, van den Brule AJ, et al: Sexually transmitted infection as a cause of anal cancer. N Engl J Med 337:1350-1358, 1997 (Pubitemid 27467769)
9. Bergquist A, Ekbom A, Olsson R, et al: Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36:321-327, 2002 (Pubitemid 34194790)
10. Koebel CM, Vermi W, Swann JB, et al: Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903-907, 2007 (Pubitemid 350231320)
11. Dougan M, Dranoff G: Immune therapy for cancer. Annu Rev Immunol 27:83-117, 2009
12. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474, 1986 (Pubitemid 17181429)
13. Okayasu I, Hatakeyama S, Yamada M, et al: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694-702, 1990 (Pubitemid 20069706)
14. Boivin GP, Washington K, Yang K, et al: Pathology of mouse models of intestinal cancer: Consensus report and recommendations. Gastroenterology 124:762-777, 2003 (Pubitemid 36268493)
15. Popivanova BK, Kitamura K, Wu Y, et al: Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118:560-570, 2008 (Pubitemid 351206546)
16. Mantovani A, Allavena P, Sica A, et al: Cancer-related inflammation. Nature 454:436-444, 2008
17. Ghosh S, Karin M: Missing pieces in the NF-kappaB puzzle. Cell 109:S81-S96, 2002 (suppl)
18. Greten FR, Eckmann L, Greten TF, et al: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285-296, 2004 (Pubitemid 39061110)
19. Eaden J, Abrams K, Ekbom A, et al: Colorectal cancer prevention in ulcerative colitis: A case-control study. Aliment Pharmacol Ther 14:145-153, 2000 (Pubitemid 30088290)
20. Kopp E, Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265:956-959, 1994
21. Jacobs EJ, Thun MJ, Bain EB, et al: A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99:608-615, 2007 (Pubitemid 47073542)
22. Kim S, Takahashi H, Lin WW, et al: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457:102-106, 2009
23. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al: Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118:229-241, 2004 (Pubitemid 38962578)
24. Rakoff-Nahoum S, Medzhitov R: Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317:124-127, 2007 (Pubitemid 47056471)
25. Pull SL, Doherty JM, Mills JC, et al: Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci U S A 102:99-104, 2005 (Pubitemid 40094435)
26. Fukata M, Michelsen KS, Eri R, et al: Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 288:G1055-G1065, 2005 (Pubitemid 40563149)
27. Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9:798-809, 2009
28. Catlett-Falcone R, Landowski TH, Oshiro MM, et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10:105-115, 1999 (Pubitemid 29077388)
29. Kujawski M, Kortylewski M, Lee H, et al: Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118:3367-3377, 2008
30. Grivennikov S, Karin E, Terzic J, et al: IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103-113, 2009
31. Wu S, Rhee KJ, Albesiano E, et al: A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15:1016-1022, 2009
32. Grady WM, Myeroff LL, Swinler SE, et al: Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 59:320-324, 1999 (Pubitemid 29048861)
33. Chung YC, Chang YF: Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83:222-226, 2003
34. Galizia G, Orditura M, Romano C, et al: Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102:169-178, 2002 (Pubitemid 34171516)
35. Langowski JL, Zhang X, Wu L, et al: IL-23 promotes tumour incidence and growth. Nature 442:461-465, 2006 (Pubitemid 44264796)
36. Chen Z, O'Shea JJ: Th17 cells: A new fate for differentiating helper T cells. Immunol Res 41:87-102, 2008
37. Wang L, Yi T, Kortylewski M, et al: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206:1457-1464, 2009
38. Kortylewski M, Xin H, Kujawski M, et al: Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15:114-123, 2009
39. Glocker EO, Kotlarz D, Boztug K, et al: Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361:2033-2045, 2009
40. Berg DJ, Kuhn R, Rajewsky K, et al: Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 96:2339-2347, 1995
41. Kuhn R, Lohler J, Rennick D, et al: Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263-274, 1993 (Pubitemid 23320290)
42. Spencer SD, Di Marco F, Hooley J, et al: The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 187:571-578, 1998 (Pubitemid 28093359)
43. Moore KW, de Waal Malefyt R, Coffman RL, et al: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-765, 2001 (Pubitemid 32368050)
44. Fiorentino DF, Zlotnik A, Vieira P, et al: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146:3444-3451, 1991
45. Becker C, Fantini MC, Schramm C, et al: TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21:491-501, 2004 (Pubitemid 39370505)
46. Gounaris E, Blatner NR, Dennis K, et al: T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res 69:5490-5497, 2009
47. Erdman SE, Sohn JJ, Rao VP, et al: CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 65:3998-4004, 2005 (Pubitemid 40775635)
48. Bertagnolli MM, Eagle CJ, Zauber AG, et al: Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 2:310-321, 2009
49. Bertagnolli MM, Eagle CJ, Zauber AG, et al: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873-884, 2006 (Pubitemid 44315980)
50. Maltby S, Khazaie K, McNagny KM: Mast cells in tumor growth: Angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 1796:19-26, 2009
51. Fox JG, Wang TC: Inflammation, atrophy, and gastric cancer. J Clin Invest 117:60-69, 2007 (Pubitemid 46048450)
52. Fox JG, Wang TC: Helicobacter pylori: Not a good bug after all! N Engl J Med 345:829-832, 2001
53. Figueiredo C, Machado JC, Pharoah P, et al: Helicobacter pylori and interleukin 1 genotyping: An opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 94:1680-1687, 2002 (Pubitemid 35446836)
54. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 87:2095-2147, 1996
55. Dolcetti L, Marigo I, Mantelli B, et al: Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett 267:216-225, 2008
56. Tu S, Bhagat G, Cui G, et al: Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14:408-419, 2008
57. Bronte-Tinkew DM, Terebiznik M, Franco A, et al: Helicobacter pylori cytotoxin-associated gene A activates the signal transducer and activator of transcription 3 pathway in vitro and in vivo. Cancer Res 69:632-639, 2009
58. Sawai N, Kita M, Kodama T, et al: Role of gamma interferon in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Infect Immun 67:279-285, 1999 (Pubitemid 29021660)
59. Smythies LE, Waites KB, Lindsey JR, et al: Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice. J Immunol 165:1022-1029, 2000 (Pubitemid 30484772)
60. Berg DJ, Lynch NA, Lynch RG, et al: Rapid development of severe hyperplastic gastritis with gastric epithelial dedifferentiation in Helicobacter felis-infected IL-10(-/-) mice. Am J Pathol 152:1377-1386, 1998
61. Eaton KA, Mefford M, Thevenot T: The role of T cell subsets and cytokines in the pathogenesis of Helicobacter pylori gastritis in mice. J Immunol 166:7456-7461, 2001 (Pubitemid 32525623)
62. Pikarsky E, Porat RM, Stein I, et al: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461-466, 2004 (Pubitemid 39329586)
63. Maeda S, Kamata H, Luo JL, et al: IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121:977-990, 2005 (Pubitemid 40884391)
64. Haybaeck J, Zeller N, Wolf MJ, et al: A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16:295-308, 2009
65. Fu YX, Huang G, Wang Y, et al: B lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin alpha-dependent fashion. J Exp Med 187:1009-1018, 1998 (Pubitemid 28176401)
66. Wang Y, Kato N, Hoshida Y, et al: Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 37:65-71, 2003 (Pubitemid 36042146)
67. Nakamoto Y, Guidotti LG, Kuhlen CV, et al: Immune pathogenesis of hepatocellular carcinoma. J Exp Med 188:341-350, 1998 (Pubitemid 28357762)
68. Pages F, Berger A, Camus M, et al: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654-2666, 2005 (Pubitemid 41817714)
69. Galon J, Costes A, Sanchez-Cabo F, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964, 2006
70. Ogino S, Nosho K, Irahara N, et al: Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 15:6412-6420, 2009
71. Gao Q, Qiu SJ, Fan J, et al: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25:2586-2593, 2007 (Pubitemid 47041232)
72. Hiraoka N, Onozato K, Kosuge T, et al: Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12:5423-5434, 2006 (Pubitemid 44497257)
73. Salter RD, Howell DN, Cresswell P: Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21:235-246, 1985 (Pubitemid 15117182)
74. Sadasivan B, Lehner PJ, Ortmann B, et al: Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 5:103-114, 1996 (Pubitemid 26301087)
75. Kloor M, Becker C, Benner A, et al: Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res 65:6418-6424, 2005 (Pubitemid 40994430)
76. Bauer S, Groh V, Wu J, et al: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727-729, 1999
77. Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3:781-790, 2003
78. McGilvray RW, Eagle RA, Watson NF, et al: NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 15:6993-7002, 2009
79. Osaki T, Saito H, Yoshikawa T, et al: Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer. Clin Cancer Res 13:382-387, 2007 (Pubitemid 46225340)
80. Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu Rev Immunol 23:515-548, 2005
81. Nomi T, Sho M, Akahori T, et al: Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13:2151-2157, 2007 (Pubitemid 46649885)
82. Ye Y, Zhou L, Xie X, et al: Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion. J Surg Oncol 100:500-504, 2009
83. Chang MH, You SL, Chen CJ, et al: Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: A 20-year follow-up study. J Natl Cancer Inst 101:1348-1355, 2009
84. Chang Y, Brewer NT, Rinas AC, et al: Evaluating the impact of human papillomavirus vaccines. Vaccine 27:4355-4362, 2009
85. Roggero E, Zucca E, Pinotti G, et al: Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 122:767-769, 1995
86. Phillips RK, Wallace MH, Lynch PM, et al: A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50:857-860, 2002 (Pubitemid 34539050)
87. Debinski HS, Trojan J, Nugent KP, et al: Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet 345:855-856, 1995
88. Hodi FS, Dranoff G: Combinatorial cancer immunotherapy. Adv Immunol 90:337-360, 2006
89. Korman A, Peggs K, Allison JP: Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:293-335, 2006